Researchers have found that a small vaccine, currently in its early trial, can mobilise the immune system to battle advanced kidney cancers.
The research team, led by Dr David Braun of the Yale Cancer Centre, said the “personalised cancer vaccines” used by nine patients in the trial were targeted to genes specific to their tumours, as per UPI.
These vaccines prompted the immune systems of patients to seek and destroy stray cancer cells which were left behind after tumour-removal surgeries.
“The idea behind this trial was to specifically steer the immune system toward a target unique to the tumour,” said Braun.
“We want to improve post-surgery treatment options that reduce the risk of the cancer coming back,” he added in a Yale news release.
The study and findings were published in the journal Nature on Wednesday.
The experiment entirely focused on patients with advanced stage 3 or 4 clear cell kidney cell carcinoma.
The Yale team explained that immune-centered therapies against cancer cells already exist but they aren’t made to target the DNA of specific tumour cell types.
The PCVs used in the new experiment were made to target gene mutations which were common to ccRCC tumours — this kind of tumours make up about 80% of all kidney cancers.
The new trial on nine patients was only carried out to see if PCV as an immunotherapy was safe for the patients.
Five of the nine patients were treated with a PCV plus the immunotherapy drug ipilimumab after they underwent surgery while the other four were given PCV treatments only after their surgeries.
All nine patients showed elevated levels of the cancer-fighting T cells that began within three weeks of treatment and lasted for years afterwards, the researchers reported.
Moreover, the T cells were also able to effectively recognise specific tumour cells in seven of the patients.
Patients didn’t complain of any side effects other than some flu-like symptoms experienced a day or two after the vaccine was administered.
